Across TCGA pan-cancer cohorts, LRRC10 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LRRC10 data layer compared with 14 for mass-spec protein.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher LRRC10 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LRRC10 expression acts as an unfavorable survival marker.
LIHC, PRAD, and UCEC are the cancer types where LRRC10 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.